Effects of Wood Smoke Constituents on Mucin Gene Expression in Mice and Human Airway Epithelial Cells and on Nasal Epithelia of Subjects with a Susceptibility Gene Variant in Tp53

Background: Exposure to wood smoke (WS) increases the risk for chronic bronchitis more than exposure to cigarette smoke (CS), but the underlying mechanisms are unclear. Objective: The effect of WS and CS on mucous cell hyperplasia in mice and in human primary airway epithelial cells (AECs) was compared with replicate the findings in human cohorts. Responsible WS constituents were identified to better delineate the pathway involved, and the role of a tumor protein p53 (Tp53) gene polymorphism was investigated. Methods: Mice and primary human AECs were exposed to WS or CS and the signaling receptor and pathway were identified using short hairpin structures, small molecule inhibitors, and Western analyses. Mass spectrometric analysis was used to identify active WS constituents. The role of a gene variant in Tp53 that modifies proline to arginine was examined using nasal brushings from study participants in the Lovelace Smokers Cohort, primary human AECs, and mice with a modified Tp53 gene. Results: WS at 25-fold lower concentration than CS increased mucin expression more efficiently in mice and in human AECs in a p53 pathway-dependent manner. Study participants who were homozygous for p53 arginine compared with the proline variant showed higher mucin 5AC (MUC5AC) mRNA levels in nasal brushings if they reported WS exposure. The WS constituent, oxalate, increased MUC5AC levels similar to the whole WS extract, especially in primary human AECs homozygous for p53 arginine, and in mice with a modified Tp53 gene. Further, the anion exchange protein, SLC26A9, when reduced, enhanced WS- and oxalate-induced mucin expression. Discussion: The potency of WS compared with CS in inducing mucin expression may explain the increased risk for chronic bronchitis in participants exposed to WS. Identification of the responsible compounds could help estimate the risk of pollutants in causing chronic bronchitis in susceptible individuals and provide strategies to improve management of lung diseases. https://doi.org/10.1289/EHP9446


Introduction
Air pollution is the biggest environmental cause of death worldwide and accounts for ∼ 5-6 million deaths every year (GBD 2013Risk Factors Collaborators et al. 2015. Chronic lung diseases are primarily caused by chronic exposure to cigarette smoke (CS) but also by biomass smoke in high-income and in low/middle-income countries, respectively (Liu et al. 2016;WHO 2013). However, not only does indoor household pollution but outdoor pollution stemming from forest fires and traffic emissions likewise contributes to respiratory diseases. Forest fires alone can account for up to 25-30% of the emissions of fine particulate matter [PM ≤2:5 lm in aerodynamic diameter (PM 2:5 )] (Perrone et al. 2012). The contribution of forest fires to air pollution is predicted to increase given that the frequency and intensity of wildfires is expected to rise owing to climate change (Oliveira et al. 2020;Ramo et al. 2021). Because wood smoke (WS) from forest fires is becoming more frequent during summer months, even in traditionally wet areas, not only households in low-income countries, but also millions of people in high-income countries, are consistently exposed to WS and experience respiratory problems (Kang et al. 2021). In addition, exposure to WS indoors has, on average, ranged from 0.05 to 1 mg=m 3 total particulate matter (TPM) concentration (Ward et al. 2017) over long periods, unlike exposure to CS, which is short-term but intense; a study evaluating the sidestream emissions of tar from 15 brands of cigarettes found a range of 15-40 mg per cigarette and 2:5-19 mg=cigarette in the mainstream smoke (Rickert et al. 1984).
Meta-analyses have demonstrated that household air pollution from WS not only increases the risk for chronic obstructive pulmonary disease (COPD) exacerbations (CDC 2010;Mannino and Buist 2007;Vestbo et al. 2013) and pneumonia (Dherani et al. 2008;Salvi and Barnes 2009), but it more than doubles the risk of COPD and chronic bronchitis (Hu et al. 2010;Kurmi et al. 2010;Po et al. 2011), and increases emergency room visits, hospitalizations ), and mortality Dominici et al. 2006;Mannino et al. 2002). Risk for chronic bronchitis increased drastically with years of cooking and WS exposure (Pérez-Padilla et al. 1996). Chronic bronchitis is a disease of large airways, defined by a persistent chronic cough and sputum production for at least 3 months per year for 2 consecutive years (GOLD 2001).
Computed tomography scans of female former cigarette smokers with COPD has suggested that the airway-predominant COPD phenotype manifested by air trapping is associated with biomass exposure, whereas the emphysematous COPD phenotype is associated with CS (Camp et al. 2014). In another study, with 27 and 21 individuals, matched by age and place of origin, with unique exposure to biomass smoke and CS, respectively, mild fibrosis in the lung parenchyma and bronchi was more common in women with WS-associated lung diseases, but emphysema and goblet cell metaplasia was more common in cigarette smokers (Rivera et al. 2008). However, why WS and CS are associated with different disease outcomes is not known.
Persons with a longer duration of chronic bronchitis symptoms are at risk for accelerated decline in lung function (Allinson et al. 2016;Vestbo et al. 1996) and were found to have a higher risk of hospitalization compared with persons with a similar level of airflow limitation who did not have chronic bronchitis (Vestbo et al. 1996). They also had increased exacerbation (Kim et al. 2011) and hospitalization (Vestbo et al. 1996) rates compared with persons with a similar level of airflow limitation who did not have chronic bronchitis. We found that self-reported exposure to WS was associated with a higher risk for chronic bronchitis symptoms and lower lung function in humans (Sood et al. 2010) and that mice exposed to WS had higher levels of smoke-induced inflammation (Awji et al. 2015).
Although all smokers develop an inflammatory response, chronic bronchitis was only observed in a subset of heavy smokers in one study (Lapperre et al. 2004), and persistent chronic bronchitis in former smokers may be due to susceptibility genes and exposure to pollution that do not allow the resolution but, rather, promote persistent inflammation (Lapperre et al. 2004). Despite the importance of chronic bronchitis, a limited number of studies have elucidated the mechanisms of WS-induced mucin production or identified susceptibility genes that enhance the risk for WS-induced chronic bronchitis.
Our previous studies in mice showed that hyperplastic mucous cells were sustained by the anti-apoptotic protein, Bcl-2 (Harris et al. 2005), and that blocking Bcl-2 reduced mucous cell hyperplasia (Chand et al. 2017). A subsequent effort to understand the regulation of Bcl-2 identified that p53 reduced Bcl-2 mRNA half-life and that p53 variants defined by a change in amino acid at codon 72 differentially interact and degrade Bcl-2 mRNA. The p53 Arg variant did not interact and reduce Bcl-2 mRNA stability as efficiently as the p53 Pro variant, but by interacting with the promoter, it enhanced the promoter activity of sterile alpha motif pointed domain containing E-twenty-six transcription factor (SPDEF) more efficiently and ultimately drove mucous cell differentiation (Chand et al. 2014).
We found that WS increased the risk of chronic bronchitis by 56% in the Lovelace Smokers' Cohort (LSC), a well-characterized cohort of smokers living in New Mexico (Bruse et al. 2011;Hobbs et al. 2017;Lange et al. 2015). Because the cohort we studied were all cigarette smokers, this finding suggested that WS has an effect that is different from that caused by cigarette smoking. This assumption was confirmed by laboratory findings in which mice exposed to 250 mg=m 3 CS for 6 h and to 10 mg=m 3 WS for an additional 2 h showed enhanced inflammatory responses compared with mice exposed to either WS or CS alone (Awji et al. 2015). Because we noticed enhanced inflammation, the present study was initiated to determine whether WS may cause enhanced expression of mucins and affect changes to the airways in a manner that CS does not. Therefore, mice and airway cells from mice and humans were exposed to WS or CS to compare their potency in inducing mucin gene expression. Further, we investigated the pathway by which WS induces mucin gene expression and identified the WS constituents responsible for mucin gene expression. We also used primary cells from mice and humans who have a modified p53 Pro or p53 Arg variant to determine whether this p53 variant differentially drives mucin gene expression in response to WS and its constituents.

Study Population
The LSC has study participants who are men and women from the Albuquerque, New Mexico, metropolitan area. Inclusion criteria for entry into the current study were being 40-75 years of age and current or former cigarette smokers (with a minimum of 10 pack-years). We have previously described the general demographic information of the LSC (Hunninghake et al. 2009;Lange et al. 2015;Silverman et al. 2011). Participants in the LSC provided informed consent, and all studies using the LSC were approved by the Western Institutional Review Board. All study participants provided information related to demographics, respiratory diseases, and smoking by self-report via a questionnaire. WS exposure was self-reported in response to the question, "Have you ever been exposed to wood smoke for 12 months or longer" as part of the general health survey. However, no additional details about type, intensity, and duration of WS exposure were obtained. Smoking-related variables included smoking in pack-years and current smoking status at the time of testing. Nasal brushings were collected using a Cyto-Pak Soft Brush from the inferior turbinate within each nostril from participants and stored at −80 C in RNasin until use. From 2,273 study participants in the LSC, nasal brushings were available from 1,988 study participants.

Study Design to Investigate the Role of the p53 Variant Using Nasal Brushings
To investigate whether mucin gene expression is affected by WS exposure and p53 variant, we first identified 70 study participants for whom nasal brushings were available and who reported exposure to WS. Of these participants, 29 were homozygous for the p53 Arg variant and 41 had at least one p53 Pro variant. Those 70 individuals were then matched by sex, age, Hispanic ethnicity, smoking history, smoking status, body mass index, chronic bronchitis, and COPD (defined by the ratio of forced expiratory volume in one second and the forced vital capacity being <70%) relative to study participants who did not report WS exposure, of whom 29 were homozygous for the p53 Arg variant and 41 had at least one p53 Pro variant (Table S1). The demographic table for the 140 selected participants by WS exposure and p53 variant is shown in Table S2. After quantitative polymerase chain reaction (qPCR) analyses for mucin 5AC (MUC5AC) and SPDEF mRNAs, 20 samples representing 10 each from WS-exposed and nonexposed group were excluded because the DCT values were >35 from a 40-cycle amplification and the samples provided unreliable numbers upon replication.

Exposure Systems for WS and CS
Mice were exposed in whole-body exposure chambers to mainstream CS from 1R3 research cigarettes (University of Kentucky Tobacco Research and Development Center, Lexington, Kentucky) as was previously described. Mice were acclimated to CS by exposing to 100 mg=m 3 of TPM (CS-100) during the first week, followed by 250 mg TPM=m 3 for 6 h/d, 5 d/wk. For generating WS, ∼ 3 kg of wood (Pinus edulis, the common pinon) was ignited in a wood burning stove with a propane torch and smoke was diverted to the exposure chambers 30 min after the fire was established. Every 15 min thereafter, 1 kg of wood was added to maintain the continuity of the fire during the 2-h exposure period, as previously described (Tesfaigzi et al. 2002). Smoke from the wood burning stove was directed and diluted to the desired concentration with air in a multitiered, whole-body exposure chamber at 10 mg=m 3 TPM (H-1000; Lab Products Inc.). A third chamber was used to expose mice to filtered air (FA) as a control. Sterile prebaked quartz (47-mm Tissuequartz) fiber filters (Pall Gellman) were used to collect TPM to determine the exposure concentrations in the exposure chambers and for preparing extracts. The 100 and 250 TPM mg=m 3 corresponds to 1.3 and 3.3 pack/d cigarette smoking (Finch et al. 1998).
Pollution from cooking indoors can reach 10-20 mg=m 3 TPM at peak cooking times (Balmes 2010); therefore, 10 mg=m 3 of TPM corresponds to a high indoor air pollution in homes using an open fire for cooking.

Mice
Male pathogen-free wild-type C57BL/6J mice were purchased from the Jackson Laboratory. Wild-type mice (p53 WT ) and mice with a modified proline-rich domain (PRD) in which the four prolines were modified to alanine (p53 AXXA ) on a 129J background were provided by G.M. Wahl (Salk Institute for Biological Studies, La Jolla, California) (Toledo et al. 2007) and backcrossed for at least 10 generations into the C57BL/6J background. The p53 AXXA mice were genotyped by standard PCR to demonstrate the different products from wild-type mice using primer sequences, as previously described (Chand et al. 2014). All mice were housed in isolated cages under specific pathogen-free conditions and bred at Lovelace Respiratory Research Institute, Albuquerque, NM and Brigham and Women's Hospital, Boston, MA. For all studies, each mouse was euthanized using 0:02 mL of Euthasol administered by intraperitoneal injection. Purchased male C57BL/6J mice were randomly assigned to six groups with four mice per group and exposed for 4 and 12 wk to FA, to WS at 10 mg=m 3 of TPM for 2/d, to CS for 6 h/d at 250 mg=m 3 TPM, or to both. Mice were euthanized 1 d after the final exposure. In addition, female p53 WT and p53 AXXA mice were randomly assigned to four groups with three mice per group and exposed to FA or WS at 10 mg=m 3 for 6 h for 1 d and euthanized the next day. Exposure to oxalate was performed by intranasal instillation, as previously described (Tesfaigzi et al. 2001). For the oxalate exposure study, equal numbers of male and female p53 WT and p53 AXXA mice were randomly assigned to four groups with six mice per group. After isoflurane anesthesia, the mice were intranasally instilled with 100 ng oxalate in 50 lL phosphate-buffered saline (PBS) or vehicle only once a day for 2 consecutive days and euthanized on the third day. All experiments were approved by the Institutional Animal Care and Use Committee and were performed at both the Lovelace Respiratory Research Institute and Brigham and Women's Hospital, facilities approved by the Association for the Assessment and Accreditation for Laboratory Animal Care International.
Right cranial, middle, and caudal lung lobes were removed from the mice, and the cranial lob tissue was homogenized using a Tissue Lyser II (Retsch) and RNA was isolated with Trizol (Invitrogen) and quantitative real-time (qRT)-PCR were performed with a one-step Taqman PCR Kit (Applied Biosystems). Left lungs were inflated and fixed overnight at 25 cm pressure with zinc formalin (Fisher Chemicals) and kept in ethanol before the preparation of 0:3-cm thick slices for embedding into paraffin. From each mouse, 5-lm thick lung tissue sections were prepared using a Leica microtome and stained with Alcian blue, hematoxylin and eosin, or were immunostained as described below using antibodies to Muc5ac and phosphorylated epidermal growth factor receptor (pEGFR), phosphorylated extracellular signalregulated kinase 1/2 (pERK1/2), or gamma histone family member X (c-H2AX). In general, two tissue sections per mouse were analyzed. Images of lung sections were captured using a NanoZoomer Digital Pathology slide scanner (Hamamatsu) and epithelial and mucous cells were quantified using Visiopharm Integration System software version 2.16.0.0, by a person who was unaware of the treatment groups.

Cell Culture
Primary human airway epithelial cells (AECs) from several donors were provided by H.W. Chu (National Jewish Health, Denver, Colorado). Cells were collected from healthy volunteers who needed bronchoscopy to confirm or exclude respiratory diseases and were stored in a deidentified manner in the National Jewish Health database, and all participants provided written informed consent. The use of human AECs was approved by the institutional review boards at National Jewish Health and at Brigham and Women's Hospital and a consent form is available. These primary cells were maintained in bronchial epithelial growth medium (BEGM) and small AEC growth media (SAGM) (both from Lonza) supplemented with growth factors (BEGM and SAGM Singlequots; Lonza) at 37°C under an atmosphere containing 5% carbon dioxide as described by Fulcher et al. (2005). Cells were seeded on 804G-coated plates and grown to 60-70% confluency and ∼ 5 × 10 5 cells were transferred onto each 12-well Transwell membrane (Corning) to allow differentiation in an air-liquid interface condition. Once cells reached complete confluence, over 1-2 d, the medium from the top compartment was removed and cells were fed only from the bottom compartment to allow the air-liquid interface differentiation to occur over 2-3 wk. Mouse AECs were harvested and cultured as previously described (You et al. 2002) and treated in the same fashion as human AECs. Mouse AECs were isolated from murine tracheas after overnight digestion with pronase and washing in PBS. After 2 wk of differentiation on the air-liquid interface, cultured human and mouse AECs that were differentiated on Transwell membranes were treated by adding 100 ng=mL WS or CS extract or 100 nM oxalate into the bottom chamber of the Transwell cultures for 24-48 h. Preparation of WS or CS extracts is described below. For CS exposure and analysis for WS-and CS-induced mRNA expression of MUC5AC and SPDEF of primary AECs, five replicates per group (n = 2) with two experimental repeats (N = 2) were used. For investigating the activation of EGFR, ERK1/2, or p53, three independent experimental repeats (N = 3) were analyzed, and in the corresponding inhibition experiments with AG1478 (10 nM), U0126 (100 nM) or Nutlin-3 (100 nM), respectively, compounds were added to the cultures 30 min before treatment with WS extract. Three independent experimental repeats (N = 3) each with two replicates (n = 2) were used for this study. Differentiated cultures were also fixed after treatment to perform immunostaining for MUC5AC, as described below, in two replicates (n = 2) from four independent experiments (N = 4). Mouse AECs from wild-type and tumor protein p53 (Tp53) knockout mice treated with WS, three replicates per group (N = 3) with three experimental repeats (N = 3) were used. Human embryonic kidney 293 (HEK293T) cells were purchased from American Type Culture Collection and were maintained in Dulbecco's Modified Eagle Medium (Sigma) with 10% fetal bovine serum (Corning) and 1% penicillin-streptomycin (Corning).

Preparation of WS and CS Extracts
WS and CS particulate matter were collected onto sterile prebaked quartz (47-mm Tissuequartz) fiber filters (Pall Gellman), with an average weight of 1-2 mg TPM/filter, and were stored at −80 C in a petri dish rapped with aluminum foil. The filters were incubated in BEGM for 60 min at 37°C to prepare a concentration of 20-40 lg=mL. The stock solution was sterilized by filtering through 0:2-lm pore sized filters (Millipore) and diluted to concentrations ranging from 10 ng=mL to 10 lg=mL for treating cells.

High-Performance Liquid Chromatography Fractionation of WS Extract and Mass Spectrometry
For WS fractionation preparation with high-performance liquid chromatography (HPLC), a working solution of 100 lL from a 100-lg=mL concentration was prepared by extracting the filter with WS TPM with dimethyl sulfoxide (DMSO) and fractionated using an Agilent model 1100 HPLC system with a Rheodyne 7725 manual injector and ChemStation software (version A.09.01 or 09.03; Agilent Technologies). For the analyses, a Luna 5-lm C-18 column (4:60 mm ID × 150 mm; Phenomenex Inc.) was used. The mobile phase consisted of purified water with 0.025% formic acid, acetonitrile with 0.025% formic acid, and 10 mM ammonium acetate in a gradient elution with a total run time of 10 min per injection. Every minute, 1-mL fractions were collected, and after brief evaporation of the mobile phase, were kept at −80 C for further testing at a different dilution for their efficiency in activating the SPDEF promoter and inducing mucin gene expression. Fractions that showed a high or low SPDEF luciferase activity (F2 and F15) and an extract prepared from a clean filter were analyzed using a gas chromatography-mass spectrometry (GC-MS) technique (Varian 4000; Ion Trap and Scion Triple Quad MS/MS). For the polar organic compounds, samples were first extracted with ethyl acetate to reduce the risk of less polar semivolatile compounds evaporating during the concentrating procedure. This step removes less polar compounds from an aqueous sample, whereas more polar compounds remain in the original sample. Briefly, a 0:5-mL aliquot of filtered (using a 0:45-lm GMF Whatman filter) sample was placed in a 4-mL vial. An equal amount of ethyl acetate was added for microextraction. Prior to that, samples were spiked with a set of internal standards (AccuStandard Inc.) Both fractions were shaken vigorously for about 10 min and left for a few hours to separate. The upper layer (ethyl acetate) was carefully removed to a separate vial. A small amount of magnesium sulfate was added to remove any residual water from that extract. Extracts were then filtered again with a 0:2-lm polytetrafluoroethylene (PTFE) Whatman filter. The entire fraction was placed into a 2-mL vial and ∼ 200 lL of acetonitrile was added to exchange solvent contents. Extracts were concentrated using a SpeedVac (Thermo Fisher) with a default vacuum pressure to the final volume of 50 lL for a silylation procedure.
The second part of the extract that contained water was taken to dryness using a SpeedVac. After adding 50 lL of acetonitrile, the extract was sonicated, and both the ethyl acetate and water fractions underwent a silylation process. Derivatization was carried out by using a mixture of 150 lL of bis(trimethylsilyl)trifluoroacetamide (with 1% trimethylchlorosilane; Sigma-Aldrich) and 50 lL of pyridine (Sigma-Aldrich) to convert polar compounds into their trimethylsilyl derivatives. Samples were placed onto thermal plates at 65°C for 2 h.
For the nonpolar fractions, a 1-mL aliquot was placed in a 4-mL vial and an equal amount of methylene chloride was added. Samples were spiked with a set of internal standards (AccuStandard Inc.) and shaken well for 10 min. The samples were then left for a few hours to separate the fractions. The methylene chloride layer was carefully removed to a separate vial and a small amount of sodium sulfate was added to remove any residual water. Extracts were then filtered again with a 0:2-lm PTFE Whatman filter. Approximately 500 lL of toluene was added and each extract was concentrated using Pierce Reacti-Therm under a gentle flow of ultra-high purity nitrogen to a final volume of 250 lL.

qRT-PCR
Total RNA from cultured cells and mouse lung tissues was extracted using the TRIZOL (TRI Reagent; Invitrogen) and concentrations were determined using a NanoDrop 1000 (Thermo Fisher Scientific). RNasin was first removed from nasal brushings by centrifugation at 200 × g for 10 min, and RNA was isolated using the RNeasy Micro Kit (Qiagen). Target mRNAs were amplified by qRT-PCR in 20-lL reactions on the real-time ABI Prism PCR system (PRISM 7900HT; Applied Biosystems) using the One-Step RT-PCR Master Mix (TaqMan; Applied Biosystems). Relative quantities from duplicate amplifications were calculated by normalizing averaged threshold cycle (Ct) values to the housekeeping gene (CDKN1B) or 18s RNA to obtain the DCT of the target gene of interest, and the relative fold change was used for determining the fold differences by subtraction from the control CT value to obtain 2 −DDCt , as described previously (Schwalm et al. 2008;Mebratu et al. 2008). The sequences of the primers (Applied Biosystems) used are provided in Table S3. In general, 100-ng total RNA was used for the qTR-PCR using a one-step qPCR program (48°C for 15 min, 96°C for 10 min, and 60°C and 96°C for 40 cycles using QuantStudio 3 (ABI).

SPDEF Promotor Luciferase Activity and Inhibition Assay
HEK293T cells were transfected with a pGL3 plasmid construct that was generated for a previous study, containing the SPDEF promotor driving a luciferase reporter gene (Chand et al. 2014). The luciferase activity was measured by activating the SPDEF promoter with total WS extract, the HPLC fractions were prepared from the WS extract, and the identified active compounds. Briefly, 50,000 cells per well were seeded in a 12-well dish and 24 h later transfected with the SPDEF promotor luciferase plasmid using Mirus 2020 transfection reagent. Cells were treated with 100 ng=mL WS extract or HPLC fractions of WS extract that were stored at −80 C, or with the identified active compounds individually or in double or triple combinations at 100 nM each, and 18 h after treatment washed once with PBS and lysed by rocking for 15 min with passive lyses buffer (Promega). Cell lysates (20 lL) were transferred in 96-well plates and SPDEF Promoter luciferase activity measured 1 min after adding 100 lL=well of Luciferase Assay Reagent II and adding Stop & Glo Reagent using Fluoroskanto Ascent (Thermo Fisher Scientific) with SpectraMax iD5 Multi-Mode Microplate Reader (Molecular Devices).
For identifying the involved receptor(s), cells were treated with inhibitors of the sodium/glucose cotransporter 1 (Phlorizin; at 1 and 10 mM), the ATP-sensitive potassium channels (glyburide, at 1 and 100 lM), the cystic fibrosis transmembrane conductance regulator (GlyH-101, at 10 and 50 lM), or inhibitors of both phospholipase A2 and 16 of SLCs (Niflumic acid, at 1, 10, and 30 lM). These inhibitors were added 30 min prior to activating the SPDEF promoter by the WS extract or the identified WS constituents.

Retroviral Silencing Using Short Hairpin RNA
Retroviral silencing vector encoding for SLC26A9 short hairpin RNA (shRNA) and control (Ctrl) vector were used. SLC26A9specific shRNA plasmids and control plasmids (OriGene Technologies; Cat. nos. TR301620 and TR30024) were directly used in transfected HEK293T cells using Mirus 2020 transfection reagent and packaged into retroviral particles using Phoenix cells (ATCC) as specified by the manufacturer's instructions. After transfecting Phoenix cells with the retroviral vector, the retroviruscontaining supernatant was collected at 48 and 72 h. The filtered (0:45 lm) supernatant that contains the packaged virus was harvested and used to infect human AECs. To generate stable human AECs expressing the SLC26A9 or Ctrl shRNAs, the viruscontaining medium was removed from the AECs after 48 h and transduced cells were selected with puromycin 1 lg=mL for another 48 h in normal growth media. The knockdown efficiency of the shRNA in human AECs was confirmed by qPCR, as detailed in the "qPCR" section and shown in Figure S3, using Taqman primers (Applied Biosystems), and reported in Table S3.

Immunofluorescence
Immunofluorescent staining and image analysis of human AECs were performed as described previously (Contreras et al. 2013). Cells were grown on Transwell membranes on an air-liquid interface in 12-well plates, and membranes were fixed with 3% paraformaldehyde with 3% sucrose in PBS for 20 min at room temperature. After fixation, the cells were washed three times with PBS/0.2% (vol/vol) Triton-X100 (Sigma-Aldrich) to remove residual mucus from the apical surface. Nonspecific binding sites were blocked with 5% (vol/vol) donkey serum (EMD Millipore), 1% (wt/vol) bovine serum albumin (BSA) and 0.2% (vol/vol) Triton-X100 in PBS for 30 min at room temperature, followed by incubation with primary antibodies in blocking buffer at 4°C overnight. Similarly, lung tissues from mice were deparaffinized, rehydrated in graded ethanol and deionized water, and washed. Sections were then incubated in 0.2% Triton X-100 with 0.2% saponin for permeabilization of cells and kept in blocking solution containing 3% immunoglobulin Gfree BSA, 1% gelatin, and 2% normal donkey serum. After incubating in relevant primary antibodies, including pEGFR (sc2342, 1:50; Santa Cruz), pERK (4695S, 1:100; Cell Signaling), c-H2AX (2577L, 1:100; Cell Signaling), and MUC5AC (sc-21701, 1:100; Santa Cruz) in blocking solution overnight at 4°C, sections were washed with blocking solution and counterstained using FðabÞ 2 fragments of the respective secondary antibodies conjugated to Dylight-549 or -649 (Jackson ImmunoResearch Laboratories) for 1 h at room temperature. After washing in PBS and mounting with glass coverslips using 4 0 ,6-diamidino-2-phenylindole containing Fluoromount-G (Southern Biotech) for nuclear staining, the fluorescently labeled cells were analyzed using an imaging system (Axioplan 2; Carl Zeiss) equipped with a charge-coupled device camera (ORCA-ER; Hamamatsu Photonics) coupled with a wavelength switch (Lambda DG-4; Sutter Instrument) and acquisition software (SlideBook 5; Intelligent Imaging Innovations).

Statistical Analysis
Grouped results from at least three different experiments were expressed as mean ± standard error of the mean (SEM). All points from the biological and the experiments replicates were presented in the scatter plot. Differences among groups were examined by analysis of variance and t-tests using Prism statistical analysis software (GraphPad Software) and by application of Tukey's test for multiple comparisons. Differences were considered significant at p < 0:05.

Results
Exposure of Mice and Primary Airway Cells to WS and CS Mice were exposed for 4 and 12 wk to either CS, WS, or FA as control. Compared with mice exposed to FA, mice exposed to 10 mg=m 3 WSY but not to 250 mg=m 3 CS had significantly more mucous cells per millimeter basal lamina in the lung tissues ( Figure 1A). Immunostaining for Muc5ac protein confirmed that WS-compared with CS-exposed mice displayed higher numbers of mucous cells at both 4 and 12 wk of exposure ( Figure 1B). In this study, mice exposed to CS did not have significantly higher Muc5ac or SPDEF mRNA levels compared with FA controls; however, mice exposed to WS showed higher both Muc5ac and SPDEF mRNA levels at 4 and 12 wk of exposure ( Figure 1C).
Further, primary human AECs that were differentiated on airliquid interface cultures were treated for 48 h to 100 ng=mL WS or CS extract. Similar to what was observed in mice, WS but not CS extract-induced expression of both MUC5AC and SPDEF in differentiated human AECs ( Figure 1D). The increase of the mucin-related mRNAs was accompanied by higher MUC5ACprotein levels in WS extract-treated cultures ( Figure 1E).
Because there are no inflammatory cells present in the differentiated airway epithelial cultures, these findings suggest that WS directly affects the airway epithelium. Several studies have reported that EGFR phosphorylation induces MUC5AC expression (Casalino-Matsuda et al. 2006;Shao et al. 2004), but the role of WS exposure in phosphorylating EGFR in increasing MUC5AC gene expression has not been reported. Differentiated primary human AECs were treated with 100 ng=mL WS or CS extract and harvested at 0, 1, 3, 8, 24, and 48 h posttreatment. The CS extract had minimal effect on EGFR phosphorylation at any time point (Figure 2A), whereas cells exposed to the WS extract had significantly higher EGFR levels from 3-48 h (Excel Table S2); higher levels of pEGFR at 1, 3, and 8 h; and higher levels of pERK1/2 starting at 1 h, with more than 3-fold higher levels at 3, 8, 24, and 48 h, although these latter time points were not statistically significantly different from control ( Figure 2A; Excel Table S2). In addition, immunostaining of lung tissue sections from mice exposed for 12 wk showed that cells exposed to WS exhibited higher levels of pEGFR and pERK1/2 ( Figure 2B). Differentiated human AECs treated with the EGFR or ERK1/2 inhibitors, AG1478 or U0126, respectively showed similar levels of MUC5AC or SPDEF mRNAs as those treated with WS and no inhibitors ( Figure 2C).
Because reactive oxygen species can cause DNA damage and p53 activation (Liu et al. 2005), we investigated whether the low concentration of WS extract may affect p53 and the DNA damage repair mechanism. Cells exposed to CS extract expressed higher protein levels of p53 at 1 h that were sustained over 48 h, whereas those exposed to WS extract demonstrated higher p53 levels beginning at 3 h ( Figure 2D). CS-exposed cells sustained higher c-H2AX levels only at 3-h posttreatment, whereas WS-exposed cells exhibited significantly higher levels at 3-8 h ( Figure 2D; Excel Table S2) and immunostaining of lung tissue sections from mice exposed for 12 wk showed a lower percentage of c-H2AX + cells in WS-exposed vs. CS-exposed mice ( Figure 2E). When treated with Nutlin-3, a small molecule that disrupts the p53-MDM2 interaction and stabilizes p53 (Vassilev et al. 2004), WSinduced MUC5AC mRNA levels were augmented in differentiated human AECs ( Figure 2F). Further, primary mouse AECs from TP53 −= − mice treated with WS extract had significantly lower Muc5ac mRNA levels than those from TP53 +=+ mice ( Figure 2G). These findings suggest that the p53 signaling pathway is central in WS extract-induced SPDEF and MUC5AC expression.

Fractionation of WS to Identify the Constituents Responsible for Mucin Gene Expression Using a Promoter-Luciferase Construct
A rapid assay was developed for identifying WS components that are responsible for inducing mucous cell differentiation by transfecting HEK293T cells with a SPDEF promoter construct driving a luciferase construct. Cells treated with WS extract at 10 and 100 ng=mL TPM concentrations compared with extracts from filters without WS showed higher SPDEF promoter activity by 2to 3-fold ( Figure S1A). The 1-mL fractions obtained from HPLC were tested at various dilutions in activating the SPDEF promoter. From two independent fractionation experiments, from among 20 fractions, the hydrophilic fractions 1, 2, and 3 showed a 6-to 8-fold higher SPDEF promoter activity compared with extracts from clean filters ( Figure 3A). Fractions 5 and 6 showed a 5-fold higher activity, and fractions 8, 9, 10, 12, and 13 showed activities ranging from 2-to 4-fold higher, whereas no difference in SPDEF promoter activity was observed with fractions 14. Fraction 15, although significantly different from untreated, was similar in activity as in fraction 14. Fraction 20 was similar to the untreated filter sample ( Figure S1B). These results suggested that in fractions 1-3 inducing compounds may have been enriched or inhibitors depleted and that the exact opposite may have happened in fractions 15 or 20. Detailed analyses by GC-MS of Figure 1. Evaluation of readouts for mucin production by Alcian blue (AB) staining, mRNA expression, and immunofluorescence in mouse tissues and primary human AECs exposed to cigarette smoke (CS) or wood smoke (WS). (A) AB and hematoxylin and eosin (AB H&E) staining of airways at generation 5 of the left lungs from male mice exposed for 4 and 12 wk to filtered air (FA), CS (250 mg=m 3 ) or WS (10 mg=m 3 ) starting from 8 to 10 wk age. Mucuspositive cells are stained with AB and quantification of the number of mucus cells per millimeter of basal lamina (MCs/mm BL) n = 4=group. (B) Immunofluorescent staining showing Muc5ac positivity (shown in red) of left lung sections from mice exposed for 12 wk to FA, WS, and CS (representative images from six images from three mice per group). (C) Muc5ac and SPDEF mRNA levels in the homogenates of the cranial lobe of the right lungs from mice exposed for 4 and 12 wk to FA, WS, and CS. Expression is presented relative to FA control. n = 4 per group with two repeat qPCR reactions. (D) Primary human AECs differentiated on Transwell cultures in air-liquid interface, treated with WS (100 ng=mL) and CS (4 lg=mL) extracts for 48 h and MUC5AC and SPDEF mRNAs levels measured by qPCR. n = 5 per group in each of N = 2 different experiments. Expression is presented relative to untreated control. (E) Immunofluorescent staining with antibodies to MUC5AC (shown in green) in differentiated human AECs treated with WS (100 ng=mL) for 48 h. Percentage mucous cells per total epithelial cells quantified from two images/well and four different Transwells. For each figure the mean ± SEM is graphed, difference * , p < 0:05; ** , p < 0:01; *** , p < 0:001 with statistical t-test. Summary data is provided in Excel Table S1. Note: AEC, airway epithelial cell; DAPI, 4 0 ,6-diamidino-2-phenylindole; HAEC, human airway epithelial cell; MAEC, mouse airway epithelial cell; MUC5AC, mucin 5AC; NT, untreated; qPCR, quantitative polymerase chain reaction; SEM, standard error of the mean; SPDEF, sterile alpha motif pointed domain containing E-twenty-six transcription factor. fractions F2 and F15 using internal standards that comprise ∼ 300 compounds identified hydrophilic and hydrophobic compounds, respectively. The main constituents of the F2 fraction were sugars ( Figure 3B), and comparison of each constituent in fractions F2 and F15 with those in the whole WS extract showed that oxalate, levunilate, xylitol, a,-D-glucose, mannose, and mannitol were represented at higher levels in the F2 fraction. The concentrations of the identified sugars and their percentages in F2 and F15 fractions are listed in Excel Table S3, and the concentrations per milligram TPM in Table S4. Of the pure sugars, only cells treated with levunilate, oxalate, and xylitol had consistently higher SPDEF promoter activity at concentrations that were found in the WS extract ( Figure 3C). We tested the effect of these sugars in combinations of two and found that only levunilate enhanced the effect of oxalate and xylitol, but not of other sugars ( Figure 3D). Cells exposed to triple combinations, containing oxalate, glucose, mannose, xylitol, or inositol with any of the other sugars did not significantly differ from the untreated control ( Figure S2). For further studies, we decided to investigate the role of oxalate further given that many reports have identified it in environmental pollutions from forest fires (Jalava et al. 2015;Tomaz et al. 2018). Differentiated human AEC cultures exposed to oxalate had higher MUC5AC and SPDEF mRNA levels ( Figure 3E) to an extent similar to what was observed by WS extract treatment ( Figure 1C), and this observation was also replicated in differentiated mouse AECs ( Figure 3F). In addition, as was observed for WS extract, cells exposed to oxalate had significantly higher p53 protein levels over an 8-to 48-h period, but c-H2AX protein levels did not differ significantly ( Figure 3G).  1, 3, 8, 24, or 48 h) and protein levels of phosphorylated ERK1/2 and EGFR were analyzed by Western blotting and normalized to GAPDH and expressed in fold change relative to time point zero. (B) Immunofluorescence staining for phosphorylated EGFR, ERK1/2 in lung tissue sections of mice exposed to WS, FA, or CS for 12 wk. (C) Human AECs treated with inhibitors of ERK1/2 (UO126) or EGFR (AG 1478) 1 h prior to treatment with WS (100 ng=mL) and/or CS (100 ng=mL) and Muc5ac and SPDEF quantified by qPCR. Data are from n = 2 replicates/group in each of N = 3 experimental repeats. (D) Human AECs treated with WS or CS extracts for the indicated times and proteins analyzed using antibodies to c-H2AX and p53 by Western blotting. (E) Immunofluorescence staining for c-H2AX in lung tissue sections of mice exposed to WS, FA, or CS for 12 wk. (F) Human AECs were treated with Nutlin-3 for 1 h prior to treatment with WS (100 ng=mL) for 48 h and mRNA levels of MUC5AC and SPDEF measured by qPCR. Data from n = 2 replicates/group in each of N = 3 experimental repeats. (G) Differentiated mouse AECs from WT and p53 knockout (p53 −= − ) mice treated with WS (100 ng=mL) extract for 48 h and mRNA levels of Muc5ac and SPDEF quantified by qPCR. Data from n = 3 replicates/group in each of N = 3 experimental repeats. For each figure the mean ± SEM is graphed, difference at * , p < 0:05; ** , p < 0:01; *** , p < 0:001 with statistical t-test. Figures for Western analyses are representative of at least three individual experiments. Summary data is provided in Excel Table S2. For (D), protein expression is presented relative to time point zero. For (C,F), mRNA expression is presented relative to untreated control. For (G), mRNA expression is presented relative to untreated WT mice. Note: AEC, airway epithelial cell; EGFR, epidermal growth factor receptor; ERK1/2, extracellular signal-regulated kinase 1/2; GADPH, glyceraldehyde-3-phosphate dehydrogenase; c-H2AX, histone family member X; HAEC, human airway epithelial cell; KO, knock out; MUC5AC, mucin 5AC; NT, untreated; p53, protein 53; qPCR, quantitative polymerase chain reaction; SEM, standard error of the mean; SPDEF, sterile alpha motif pointed domain containing E-twenty-six transcription factor; WT, wild type.

Identification of the Responsible Cell Surface Proteins for Oxalate-Induced Mucin Expression Using Different Inhibitors
To identify the cell surface receptor responsible for the observed oxalate-induced SPDEF promoter activity and MUC5AC mRNA expression, we used different inhibitors that block sugar and anion transport activity. Cells treated with WS and inhibitors of the sodium/glucose cotransporter 1 (Phlorizin) and the ATPsensitive potassium channels (glyburide) or cystic fibrosis transmembrane conductance regulator (GlyH-101) did not differ significantly from those with WS alone with regard to SPDEF promotor activity ( Figure 4A). However, cells treated with WS and 10 and 30 lM niflumic acid, an inhibitor of both phospholipase A2 and 16 of SLCs, had higher SPDEF promotor activity than those treated with WS extract alone (100 ng=mL) ( Figure  4A). SPDEF promoter activity by WS extract or oxalate was higher in AECs treated with niflumic acid in a dose-dependent manner at 1, 10, and 30 lM concentrations ( Figure 4B). Among the SLC family inhibited by niflumic acid, only SLC26A9 and SLC26A4 are known to be expressed in AECs (Lohi et al. 2002;Simão et al. 2013), and SLC26A9 is a constitutively active CFTR-regulated channel in bronchial cells (Chang et al. 2009). Therefore, we suppressed SLC26A9 mRNA levels using a short hairpin construct ( Figure S3A) and found that SPDEF promoter activity was significantly higher when cells were treated with WS extract or oxalate, compared with short hairpin Control (shCTRL) constructs ( Figure 4C). The role of SLC26A9 was confirmed as suppressing SLC26A9 levels using shSLC26A9 in differentiated primary human AECs ( Figure S3B) enhanced both WS extract-or oxalate-induced MUC5AC and SPDEF mRNA levels compared with shCTRL-infected cultures ( Figure 4D).

Testing of WS-Induced Mucous Cell Metaplasia and Mucin Gene Expression in Humans and Mice and AECs with Modifications in the PRD of p53
We have previously reported that the single nucleotide polymorphism, rs1042522, which substitutes a proline (CCC) to arginine (CCG) at codon 72 within the PRD of p53, affects Bcl-2 mRNA (C) SPDEF promoter luciferase activity after treatment with WS extract or sugars found in fraction 2. Cells were treated with 100 nM of all sugars except for maltitol-b at 10 nM. Data from n = 2 replicates/group in each of N = 3 experimental repeats. (D) SPDEF promoter luciferase activity after treatment with WS extract or combinations of sugars found in fraction 2. Data from n = 2 replicates/group in each of N = 3 experimental repeats. (E) mRNA expression of MUC5AC or SPDEF from primary human AECs differentiated on Transwell membranes and treated with oxalate 100 nM for 48 h. Data from n = 2 replicates/group in each of N = 3 experimental repeats, and (F) MUC5AC and SPDEF mRNA levels quantified by qPCR from mouse AECs exposed to 100 nM oxalate or left untreated for 48 h. Data from n = 2 replicates/group in each of N = 3 experimental repeats. (G) Human AECs were treated with 100 ng=mL oxalate for indicated times (0, 1, 3, 8, 24, or 48) and p53 and c-H2AX protein levels measured by Western blotting. Image is representative of N = 3 experimental repeats. For each figure the mean ± SEM is graphed, difference at * , p < 0:05; ** , p < 0:01; *** , p < 0:001 with statistical t-test. For (A,C-F), luciferase activity and mRNA expression are graphed relative to the untreated control. For (G), protein expression is presented relative to time point zero. Summary data is provided in Excel Table S3. Note: AEC, airway epithelial cell; GC-MS, gas chromatography-mass spectrometry; c-H2AX, gamma histone family member X; HAEC, human airway epithelial cell; Muc5ac, mucin 5ac; NT, untreated; p53, protein 53; qPCR, quantitative polymerase chain reaction; SEM, standard error of the mean; SPDEF, sterile alpha motif pointed domain containing E-twenty-six transcription factor.
half-life and SPDEF promoter activity (Chand et al. 2014). We evaluated the mRNA levels of MUC5AC in nasal brushings from cigarette smokers who self-reported WS exposure by p53 variant (p53 Arg=Arg and p53 Pro=Pro ). Although MUC5AC mRNA levels in nasal brushings of WS-exposed compared with nonexposed cigarette smokers were not statistically significant by p53 variant (Figure S4), the ratios of MUC5AC in WS-exposed to nonexposed participants was higher in participants homozygous for the p53 Arg variant compared with the p53 Arg=Pro and p53 Pro=Pro variants combined ( Figure 5A). Further, differentiated human AECs homozygous for the p53 Arg compared with p53 Pro variant showed higher expression of MUC5AC, but not SPDEF, mRNA when treated with 100 ng=mL WS extract ( Figure 5B) and 10 ng=mL oxalate ( Figure 5C). Differentiated primary AECs from p53 AXXA mice treated with oxalate had higher expression of Muc5ac but not SPDEF mRNA compared with those from p53 WT mice ( Figure  5D). In addition, p53 AXXA compared with p53 WT mice exposed to WS for 6 h showed higher levels of Muc5ac and SPDEF mRNAs in their lungs ( Figure 5E). Further, 48 h after intranasal instillation of oxalate, the number of mucous cells per millimeter basal lamina were higher in p53 AXXA but not p53 WT mice ( Figure 5F).

Discussion
The present studies demonstrate that treatment of AECs with WS compared with CS exposure resulted in p53 activation as suggested by higher levels of p53 protein and higher phosphorylation levels of EGFR and ERK1/2. We found that MUC5AC gene expression was driven by the p53 pathway. Further, we showed that a major component of the WS mediating these outcomes was sugars. We propose that this represents a new pathway for mucin gene expression and have evaluated a role for a p53 Arg variant in this pathway. The observation that WS and its constituents caused higher mucin gene expression in differentiated air-liquid interface cultures supports the idea that these sugars can activate mucin expression pathway independent of cellular infiltrates.
The gases and the TPM generated by cigarettes and wood burning are similar (Pryor 1992;Tesfaigzi et al. 2002), consisting of primarily carbon black particles and organic compounds, many of which have yet to be identified. However, differences in the effects of WS and CS on cells have been reported. Chronic exposure to biomass smoke compared with CS was associated with higher levels of distinct circulating inflammatory cytokine alterations in healthy women (Falfán-Valencia et al. 2020). In addition, extracts of ambient particulate matter from WS compared with CS had a 30-fold greater potency in a mouse skin tumor induction assay (Cupitt et al. 1994;Naeher et al. 2007). These findings suggest that WS could contribute to the pathological mucus overproduction observed in patients with COPD. Consistent with our findings, a computed tomography scan study of participants with COPD suggested that WS exposure and cigarette smoking are associated with the airwayand the emphysema-predominant COPD phenotype, respectively (Camp et al. 2014;Ramírez-Venegas et al. 2006). Collectively, our findings establish a mechanistic link to previous reports that exposure to WS causes airway-predominant rather than emphysema-predominant COPD. . MUC5AC and SPDEF mRNA levels quantified by qPCR. Data from n = 2 replicates/group in each of N = 2 experimental repeats. Data graphed relative to NT. Fold differences for gene expression levels of qRT-PCR were calculated using the 2 −DDCt method, normalizing all 2 −DDCt to nontreated controls and calculating the mean fold differences for the nontreated, the WS -, and oxalate-treated groups. For each figure the mean ± SEM is graphed, difference at * , p < 0:05; ** , p < 0:01; *** , p < 0:001 with statistical t-test. Summary data is provided in Excel Table S4. Note: AEC, airway epithelial cell; ATP, adenosine triphosphate; MUC5AC, mucin 5AC; SEM, standard error of the mean; SPDEF, sterile alpha motif pointed domain containing E-twenty-six transcription factor; qRT-PCR, quantitative real-time polymerase chain reaction; shCTRL, short hairpin control; SLC26A9, solute carrier family 26, member 9; WSE, wood smoke extract.
Although both WS and CS activated the EGFR/ERK pathway, activation occurred earlier by CS than WS exposure and the stronger activation of the EGFR/ERK1/2 pathway by WS may have roles other than mucin gene expression and needs further investigation. It is well established that mucin gene expression is driven by the EGFR and ERK1/2 activation pathway in response to many stimuli, including CS (Gensch et al. 2004;Lemjabbar and Basbaum 2002), nitric oxide (Song et al. 2007), insulin-like growth factor 1 (Bae et al. 2013;Chand et al. 2012aChand et al. , 2012b, interleukin-1beta (IL-1b) (Song et al. 2003), IL-17 (Chen et al. 2003;Inoue et al. 2006), and matrix metalloproteinases (Deshmukh et al. 2005(Deshmukh et al. , 2009. Another study reported that the particulate matter of WS when administered to human bronchial epithelial cells, activated EGFR and led to MUC5AC expression (Memon et al. 2020). The difference between our findings and that report may be in the components used for activating EGFR. EGFR can be activated at various sites of phosphorylation, leading to different downstream effects (Tong et al. 2014). Because our study focused primarily on water-soluble extracts of WS particulate matter, we found that the sugars modulated p53 rather than the EGFR/ERK1/2 pathway to induce SPDEF and MUC5AC expression. Following doublestranded DNA strand breaks, p53 levels increase because of stabilization (Kubbutat et al. 1997) and histone H2AX is rapidly phosphorylated by kinases at or near the vicinity of the DNA damage sites to form c-H2AX (Fernandez-Capetillo et al. 2004). Although both WS and CS activated p53, the activation of p53 by CS occurred earlier and the activation by WS lasted over a longer period. This prolonged activation may play a role in driving SPDEF expression and the mucous cell differentiation process.
Using chromosome immunoprecipitation, we previously established that the p53 arginine rather than the p53 proline variant interacted and drove the SPDEF promoter both in human and primary mouse AECs (Chand et al. 2014) and that WS activated the p53 arginine variant. The SPDEF promoter was driven more by the p53 arginine variant compared with the p53 proline variant and led to increased mucin production in human AECs (Chand et al. 2014). The solute carrier 26 gene family located at the plasma membrane of epithelial cells transports a variety of monovalent and divalent anions, including oxalate (El Khouri and Touré 2014). The suppression of SLC26A9 in HAEC Arg cultures led to an increase of WS-and oxalate-induced MUC5AC levels. Although IL-13stimulated goblet cell metaplasia was similar in both SLC26A9 +=+ and SLC26A9 −= − mice, SLC26A9 −= − mice displayed increased airway mucus volume density and airway mucus obstruction of airways likely because chloride secretion facilitated the mucus obstruction (Anagnostopoulou et al. 2012). Mice were instilled with 5 lg IL-13 on 3 consecutive days, and IL-13 may induce mucin gene expression by mechanisms different from what is observed by oxalate. When the anion exchanger is removed, it is likely that intracellular oxalate levels are increased, thereby increasing the formation of intracellular reactive oxygen species. Because we would expect that oxalate levels would increase in the extracellular space of WS-exposed cells, reducing the levels of SLC26A9 would likely increase intracellular oxalate levels and thereby increase mucin gene expression.
For the chemical analyses, the WS extract was prepared in DMSO to capture not only the hydrophilic but also the hydrophobic compounds. The goal was to test the capacity of all WS components in inducing mucin gene expression. As indicated by the initial studies, the findings confirmed that water-soluble compounds were effective compounds in inducing mucin gene expression. The results support the idea that the effective compounds we had extracted from the filters were unlikely to be in the volatile portion or may have been affected by storage of the Figure 5. Evaluation of mucin gene expression by p53 genotype in nasal brushings of people exposed to wood smoke (WS) and the role of oxalate in mice and airway epithelial cells (AECs). (A) MUC5AC mRNA in nasal brushings from nonexposed (NE) and WS-exposed participants. The ratios of fold differences from WSexposed to the average of NE are shown (N = 60 ratios for p53 ArgArg and p53 ProPro and N = 30 ratios for p53 ArgArg ). (A,B): Expression of MUC5AC and SPDEF mRNA relative fold levels to p53 ProPro in differentiated human AECs obtained from humans homozygous for the p53 arginine and p53 proline variants exposed to either (B) 100 ng=mL WS or (C) 10 ng=mL oxalate for 48 h. Data from n = 2 replicates/group in each of N = 3 experimental repeats, the mean ± SEM is graphed, * , different from p53 proline (p < 0:05) with statistical t-test. (D) Differentiated mouse AECs from wild-type (WT) or p53 AxxA mice treated with WS (100 ng=mL) extract for 48 h and Muc5ac and SPDEF mRNA relative fold levels to WT, quantified by qPCR. Data from n = 2 replicates/group in each of N = 2 experimental repeats, the mean ± SEM is graphed, * , different from WT (p < 0:05) with statistical t-test. (E) Muc5ac and SPDEF mRNA levels in the right cranial lobes from female mice exposed to WS for 1 d at 8-10 wk of age. Data from n = 3 replicates/group (F) Mucus cells per millimeter of basal lamina (BL) in the left lung sections of 21 WT and 28 p53 AXXA mice 1 d after instillation with oxalate (6 male and 6 female WT and 8 male and 8 female p53 AXXA mice) or PBS (4 male and 5 female WT and 6 male and 6 female p53 AXXA mice) at 8-10 wk of age. Data from n = 3 replicates/group in each of N = 3 experimental repeats, the mean ± SEM is graphed, * , significantly different from PBS instilled group (p < 0:05) with statistical t-test. Representative images of airways from these mice shows mucous cells stained with Alcian blue. Summary data is found in Excel Table S5. Note: HAECs, human airway epithelial cells; MAECs, mouse airway epithelial cells; MUC5AC, mucin 5AC; PBS, phosphate-buffered saline; Oxa, oxalate; SEM, standard error of the mean; SPDEF, sterile alpha motif pointed domain containing E-twenty-six transcription factor; qPCR, quantitative polymerase chain reaction; WSE, wood smoke exposed.
filters, although future studies are needed to investigate whether other compounds in the volatile portion may also have mucininducing properties. Although smoke and filters can be contaminated with lipopolysaccharide (LPS), our studies showed that certain purified sugars activated the SPDEF promoter, leading to higher MUC5AC expression. The concentration of LPS needed to induce MUC5AC expression is in the microgram range (Tokita et al. 2014), whereas the concentrations we are using for oxalate is 100 ng. This discrepancy supports the idea that LPS, as a contaminant in the oxalate preparation, was not causing MUC5AC expression. Oxalate has also been found in the dust from urban air (Jalava et al. 2015), but a more detailed analysis of the proportions in compounds that ultimately lead to mucin production is needed. CS also contains oxalate (Gu et al. 2016); however, whether the proportions of oxalate and inhibitors are present in CS at different proportions and, therefore, inhibit their effect is currently unknown. Further, volatile components, such as acrolein, known to induce mucin expression (Borchers et al. 1999;Deshmukh et al. 2009), were excluded in our study, which focused on extracts from the TPM. Such analyses will help assess a more detailed documentation of pollutants in epidemiological studies to ultimately determine health effects. Intake of high fructose corn syrupsweetened soft drinks is associated with prevalent chronic bronchitis in U.S. adults, 20-55 years of age (DeChristopher et al. 2015). The risk for chronic bronchitis and dyspnea in participants with diabetes is increased by 2-to 3-fold, especially in individuals 55-74 years of age (De Santi et al. 2017). However, the mechanisms for circulating sugars increasing the risk for chronic bronchitis may be by increasing intracellular reactive oxygen species through hypoxia-inducing factor-1 (Codo et al. 2020) and different than the mechanism we describe in this study, which involves SLC26A9.
Studies to identify genetic polymorphisms associated with chronic bronchitis have not been reproducible across cohorts (Dijkstra et al. 2015;Lee et al. 2014;Silverman et al. 2002). In addition to the differences in the selection of the comparison groups, the present study suggests that reproducible results may also be hampered by the possibility that, depending on their composition, various pollutants affect different susceptibility genes to increase risk for chronic bronchitis. The present study shows that although WS and CS have largely comparable compositions, their effects on the cell and mucin gene expression are vastly different. Generally, airway pollution measured by respirable particles ≤2:5 mm in aerodynamic diameter was associated with lung function in Chinese adults (Xue et al. 2021). Comparison of participants with only chronic bronchitis to healthy controls by air pollutants is difficult owing to the limited number of participants in even large COPD cohorts. Therefore, detailed and rigorous analyses of pollutants to define environmental exposures, also in occupational settings, and a large number of wellphenotyped individuals are required to elucidate gene-environment interactions.
Our study has several limitations: The direct effect of expressing higher levels of MUC5AC on mucus viscosity has not been studied, and whether WS affects expression of other mucin genes will need to be investigated in the future. Further, this study does not compare whether other wood types and burning conditions have a similar effect as burning pine as described in this study. The effect of increased MUC5AC expression on diseases such as chronic bronchitis needs to be studied in larger wellcharacterized populations who have documented WS exposure to replicate our epidemiological finding. Studies to replicate our findings using cohorts with reported exposure to dust and fumes, as in the COPDGene Study, showed no association with the Tp53 genotype. However, our findings in mice that modification of the prolines in the PRD of p53 increases mucin production in response to WS and oxalate confirms the finding in humans. This mouse model may provide a tool for more mechanistic investigations into susceptibility to various pollutants and active components. Such controlled studies may provide the opportunity to model polygenic risk interactions and lay the foundation for designing cohort studies with the number of individuals that will allow targeted gene-environment interaction analyses.